Reducing the formation of Ang II by ACEi or antagonizing its effect by blocking the AT1R through ARBs may be a suitable strategy for reducing symptoms of COVID-19 patients (Schiffrin et al., 2020). This evidence concerns the gene AGTR1 and COVID-19.